
Lifecore Biomedical fell 19.1% from $7.90 to $6.39, behind the S&P 500's +10.0%. Its worst day was Mar 16 (−33.3%), and its low came Mar 27 at $3.66.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Lifecore Biomedical closed at its highest level of the year, 11.6% above where the year started.
+2.8% · S&P 500 +0.5%
EPS of $-0.16 was reported on $35.7M revenue; FY revenue guidance of $120.0M–$125.0M against the $75.1M consensus.
Story events cover the past 12 months · Times ET
−33.3%, the year's worst day · S&P 500 +1.0%
Lifecore Biomedical closed at its lowest level of the year, 53.7% below where the year started.
−5.4% · S&P 500 −1.7%
EPS of $-0.43 missed the $-0.28 estimate on $23.2M revenue (est. $26.3M); FY revenue guidance of $120.0M–$125.0M against the $122.6M consensus.
−3.9% · S&P 500 +1.4%
EPS of $-0.19 beat the $-0.21 estimate on $34.2M revenue (est. $32.1M); FY revenue guidance of $120.0M–$125.0M against the $122.0M consensus.
+2.1% · S&P 500 −0.2%
Lifecore Biomedical shares rose 55.2%, while the S&P 500 fell 0.7%.
+55.2%, the year's best day, on 4M shares, the year's heaviest volume · S&P 500 −0.7%
EPS of $-1.08 missed the $-0.30 estimate on $25.3M revenue (est. $25.6M).
+0.3% · S&P 500 +1.7%
Where it ended: a close of $6.39 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 15, 2027 (EPS est. $-0.11, revenue est. $37.7M).
Nothing in the past 12 months.
All LFCR dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LFCR and SPY from Benzinga historical bars. Not investment advice.